Erdafitinib and its Impurities

Erdafitinib is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) approved for treatment of cancer and marketed under the name Balversa. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival. Reference standards of Erdafitinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.